Gastroduodenal ulceration and bleeding are the major limitations to the use of non-steroidal anti-in¯ammatory drugs (NSAIDs). The development of safer NSAIDs or of eective therapies for the prevention of the adverse eects of existing NSAIDs requires a better understanding of the pathogenesis of NSAID-induced ulcer disease. NSAIDs can cause damage to the gastroduodenal mucosa via several mechanisms, including the topical irritant eect of these drugs on the epithelium, impairment of the barrier properties of the mucosa, suppression of gastric prostaglandin synthesis, reduction of gastric mucosal blood¯ow and interference with the repair of super®cial injury. The presence of acid in the lumen of the stomach also contributes to the pathogenesis of NSAID-induced ulcers and bleeding, by impairing the restitution process, interfering with haemostasis and inactivating several growth factors that are important in mucosal defence and repair. In recent years, a fuller understanding of the pathogenesis of NSAID-induced ulcer disease has facilitated some new, very promising approaches to the development of stomach-sparing NSAIDs.
reduce the toxicity of existing NSAIDs, depends upon clearly understanding the pathogenesis of NSAID-induced ulceration. In this chapter, the mechanisms by which NSAIDs damage the mucosa, interfere with repair and promote bleeding will be reviewed. In general, the properties of NSAIDs that contribute to ulcerogenesis can be divided into two categories: (1) topical irritancy, and (2) the suppression of prostaglandin synthase activity. In addition, the presence in the stomach and duodenum of acid and, in some cases, Helicobacter pylori (H. pylori), may contribute to the ability of NSAIDs to damage the mucosa.
TOPICAL IRRITATION OF THE MUCOSA
Studies in the 1960s by Davenport suggested that aspirin could directly damage the gastric epithelium. 5 The breaking of the`barrier' permitted the back-diusion of acid into the mucosa, which eventually led to the rupture of mucosal blood vessels. These topical irritant properties were subsequently found to be predominantly associated with those NSAIDs with a carboxylic acid residue. The unionized forms of these drugs can enter epithelial cells in the stomach and duodenum. Once in the neutral intracellular environment, the drugs are converted to an ionized state and cannot diuse out. This has been referred to as`ion trapping'. 6 As the drug accumulates within the epithelial cell, the osmotic movement of water into the cell results in swelling of the epithelial cell, eventually to the point of lysis. 6, 7 Another mechanism by which NSAIDs could damage the gastroduodenal epithelium is via the uncoupling of oxidative phosphorylation in the epithelial cells. 7, 8 Various NSAIDs have been shown to uncouple mitochondrial respiration 7, 8 , leading to a depletion of ATP and therefore a reduced ability to regulate normal cellular functions, such as the maintenance of intracellular pH. The ability of NSAIDs to uncouple oxidative phosphorylation also appears to be related to some extent to acidic moieties (such as carboxylic acid residues), since substitution at these sites interferes with the ability of these compounds to act as uncouplers. 8 The theory that NSAIDs cause topical injury by virtue of their eects on mitochondrial respiration has been challenged, mainly based on the observation that gastric and duodenal ulcers are observed following the parenteral or rectal administration of NSAIDs 9, 10 . Erosions and ulcers can also be produced in experimental circumstances in which NSAIDs are administered parenterally. 11 It is also dicult to comprehend how the uncoupling of oxidative phosphorylation would occur in gastrointestinal epithelial cells but not in the numerous other cells with which an NSAID would have contact subsequent to its absorption. On the other hand, the small intestine would be repeatedly exposed to NSAIDs that are excreted in bile and recycled enterohepatically, so it is conceivable that the uncoupling of oxidative phosphorylation is an important component of the pathogenesis of NSAID-induced enteropathy.
A third mechanism that could account for the topical irritant properties of NSAIDs is their ability to decrease the hydrophobicity of the mucus gel layer in the stomach. Lichtenberger and co-workers have proposed that this layer is a primary barrier to acid-induced damage in the stomach.
12, 13 They demonstrated that the surface of the stomach is hydrophobic and that this hydrophobicity can be reduced by various pharmacological agents. For example, NSAIDs were shown to associate with the surface-active phospholipids within the mucus gel layer, thereby reducing its hydrophobic properties. 13±15 These investigators further demonstrated that the mucus gel layer in the stomach of rats and mice given NSAIDs was converted from a non-wettable to a wettable state. This eect was found to persist for several weeks or months after the cessation of NSAID administration.
12,14
Attempts have been made to produce NSAIDs with reduced topical irritant eects. These include formulations in slow-release or enteric coated tablets, as well as the preparation of the drug as a pro-drug that requires hepatic metabolism in order to be active (e.g. sulindac). However, the incidence of gastroduodenal ulceration with prodrugs is comparable to that seen with standard NSAIDs.
16±18 This is taken as evidence that the topical irritant properties of NSAIDs are not paramount in terms of their ability to induce frank ulceration in the stomach. However, one cannot completely exclude this possibility. Most NSAIDs are excreted in bile. Even with parenteral administration of the NSAID, therefore, a re¯ux of duodenal contents into the stomach would result in the topical exposure of the gastric mucosa to these drugs.
Eorts have recently been made to develop gastrointestinally safe NSAIDs on the basis of a reduced ability to interfere with the surface-active phospholipid layer in the gastrointestinal mucus. Lichtenberger et al proposed that pre-associating NSAIDs with zwitterionic phospholipids prior to their administration should reduce the ability of the NSAIDs to associate the phospholipids in the mucus gel, and should therefore reduce their ulcerogenicity.
12 They demonstrated this to be the case by pre-associating aspirin and other NSAIDs with dipalmitoyl-phosphatidylcholine (DPPC) and demonstrating that the complex produced signi®cantly less damage in the gastrointestinal tract than did the parent drug.
14 Importantly, the pre-association of aspirin with DPPC did not interfere with the eectiveness of the aspirin to reduce fever or in¯am-mation. 19 Similar eects could be obtained with other NSAIDs.
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SUPPRESSION OF PROSTAGLANDIN SYNTHESIS
Vane's discovery in 1971 that NSAIDs inhibit prostaglandin synthesis 20 led directly to the discovery of the ability of minute quantities of exogenous prostaglandins to protect the gastrointestinal tract from injury induced by topical irritants and NSAIDs. 21 This in turn led to extensive research into the roles of prostaglandins in mucosal defence. There is substantial evidence that the ability of an NSAID to cause gastric damage correlates well with its ability to suppress gastric prostaglandin synthesis 22±25 ; agents that are weak inhibitors of gastric prostaglandin synthesis are less ulcerogenic. 24, 25 There is also a good correlation between the time-and dose-dependency of suppression of gastric prostaglandin synthesis by NSAIDs and their ability to cause gastric ulcers. 22±24 Why does the suppression of gastric prostaglandin synthesis lead to mucosal injury? As mentioned above, it is now clear that prostaglandins play a central role in modulating mucosal defence. Endogenous prostaglandins are involved in the regulation of mucus and bicarbonate secretion by the gastric and duodenal epithelium, mucosal blood¯ow, epithelial cell proliferation, epithelial restitution and mucosal immunocyte function. 26 This is not to say that prostaglandins are the only endogenous substances regulating these components of mucosal defence; indeed, nitric oxide appears to perform many of the same functions as the prostaglandins in this respect. 26 Thus, the inhibition of prostaglandin synthesis alone may not result in the formation of gastric erosions or ulcers. For example, mice in which the gene for cyclo-oxygenase-1 was disrupted exhibited negligible levels of gastric prostaglandin synthesis yet did not spontaneously develop gastric erosions or ulcers. 27 Of course, one would, in such a situation, anticipate that adaptation of the stomach to the chronic absence of prostaglandins would occur (i.e. there might be an enhanced production of other gastroprotective substances). On the other hand, the suppression of mucosal prostaglandin synthesis, while not necessarily resulting in ulcer formation, will reduce the ability of the gastric mucosa to defend itself against luminal irritants. This has been demonstrated very clearly in experimental animals. Doses of NSAIDs that substantially reduced mucosal prostaglandin synthesis did not cause overt gastric injury but did greatly increase the susceptibility of the gastric mucosa to damage induced by irritants (e.g. bile salts). 28 In terms of the pathogenesis of ulcer disease, is there one component of mucosal defence that is more important than others with respect to its impairment by NSAIDs? This question has not yet been completely answered. The fact that gastric ulcers can be induced by parenterally administered NSAIDs
9±11
, and that this damage can be produced independently of the presence of luminal acid 29, 30 , suggests that the impairment of mucus and/or bicarbonate secretion may be of lesser signi®cance. While prostaglandins are extremely potent inhibitors of mast cell degranulation 31 , and mast cells are capable of releasing a variety of mediators (e.g. leukotriene C 4 and plateletactivating factor) that can contribute to mucosal injury 32, 33 , the eects of NSAIDs on mast cells do not seem to be crucial to the pathogenesis of mucosal injury. This latter conclusion is based on the observation that rats in which mucosal mast cells have been depleted by chemical means, or mice that are genetically de®cient of mast cells, exhibit similar susceptibility to NSAID-induced gastric injury as do their respective controls. 34 The rate of epithelial turnover has been shown to be reduced by NSAIDs and could contribute to the pathogenesis of ulcer disease. 35 However, it is unlikely that this eect is the principal one that leads to the development of an ulcer.
The component of mucosal defence that appears to be most profoundly altered by NSAIDs is the gastric microcirculatory response to injury. When the mucosa is exposed to an irritant, or when super®cial epithelial injury occurs, mucosal blood¯ow substantially increases. This is probably a response aimed at removing any toxins or bacterial products that enter the lamina propria, neutralizing back-diusing acid and contributing to the formation of a microenvironment at the surface of the mucosa that is conducive to repair. 36 As described in greater detail below NSAIDs can reduce gastric mucosal blood¯ow and profoundly alter the behaviour of neutrophils¯owing through the gastric microcirculation.
EFFECTS ON THE MICROCIRCULATION
The ability of NSAIDs to reduce gastric mucosal blood¯ow has been recognized for several decades. 37±39 Prostaglandins of the E and I series are potent vasodilators that are continuously produced by the vascular endothelium, so the inhibition of their synthesis by an NSAID leads to a reduction in vascular tone. Several lines of evidence have suggested that damage to the vascular endothelium is an early event following the administration of NSAIDs to experimental animals. 40, 41 Endothelial injury is also an early event in the pathogenesis of gastrointestinal damage associated with ischaemia± reperfusion 42 , in which neutrophils have been demonstrated to play a critical role as mediators of endothelial injury. 43 This observation led us to examine the possible role of the neutrophil in the pathogenesis of experimental NSAID gastropathy (Figure 1) .
Our studies and those of others demonstrated that NSAID administration to rats resulted in a rapid and signi®cant increase in the number of neutrophils adhering to the vascular endothelium in both gastric and mesenteric venules. 25,44±46 This eect was typically seen within 15±60 minutes after the administration of an NSAID, consistent with the period of time required for the suppression of prostaglandin synthesis by these drugs. 47 Subsequent studies demonstrated that this adherence was dependent on the expression of the b 2 -integrins (CD11/CD18) on the neutrophil and intercellular adhesion molecule-1 (ICAM-1) on the vascular endothelium. 46 Such adherence could also be demonstrated to occur in vitro using isolated human neutrophils and endothelial cells from human umbilical vein. 48 Furthermore, the upregulation of ICAM-1 on the vascular endothelium in the gastric microcirculation was shown to occur within 15±30 minutes of the administration of an NSAID to rats, and this could be prevented by the administration of exogenous prostaglandins. 49 Of course, the fact that neutrophils adhere to the vascular endothelium following NSAID administration does not necessarily mean that these cells contribute to the endothelial injury of the mucosal tissue injury that can be induced by NSAIDs. To test this hypothesis, a number of studies were carried out. First, we demonstrated that depleting circulating neutrophils in the rat, either with an anti-neutrophil serum or with methotrexate, greatly reduced the severity of the gastric damage induced by indomethacin or naproxen. 50 Importantly, the induction of neutropenia also prevented the damage to the vascular endothelium induced by the NSAIDs. 50 Second, we demonstrated that treating rabbits or rats with monoclonal antibodies that blocked NSAID-induced neutrophil adherence to the vascular endothelium also markedly reduced the extent of NSAID-induced gastric damage.
41, 46 Third, we found that administration of prostaglandins at doses previously shown to prevent gastric injury prevented NSAID-induced leukocyte adherence. 44, 45 Further evidence for a link between neutrophil adherence and NSAID-induced gastric injury came from studies of arthritic rats. 51 These animals, like humans with rheumatoid arthritis, exhibit an increased susceptibility to NSAID-induced gastric damage. Interestingly, these rats also exhibited an increased level of neutrophil adherence to the vascular endothelium. This appeared to be due to an increase in expression of ICAM-1 on the vascular endothelium of arthritic rats, since pre-treatment with an antibody against ICAM-1 reduced leukocyte adherence and the susceptibility to NSAID-induced gastric damage to levels seen in healthy controls. 51 These studies suggest that, in response to the suppression of prostaglandin synthesis by NSAIDs, there is a rapid upregulation of expression of ICAM-1 on the vascular endothelium and possibly an upregulation of b 2 -integrin expression on circulating neutrophils, resulting in an increased adherence of neutrophils to the endothelium. This begs the question of whether the enhanced adhesion molecule expression is purely a consequence of the reduction of prostaglandin synthesis, or whether there is another chemical signal produced in response to diminished prostaglandin synthesis that triggers the events leading to neutrophil adherence.
Santucci et al suggested that tumour necrosis factor-a (TNFa) might be the key signal for NSAID-induced neutrophil adherence within the gastric microcirculation. 52 The release of TNFa from macrophages and mast cells has been shown to be suppressed by prostaglandins 31, 53 , and TNFa is a well-characterized stimulus for adhesion molecule expression. 54 Santucci et al demonstrated that the levels of TNFa in the plasma of rats signi®cantly increased following the administration of indomethacin, this being accompanied by a parallel accumulation of neutrophils within the gastric microcirculation and the development of gastric injury. 52 Furthermore, pre-treatment with a TNFa synthesis inhibitor, pentoxifylline, dose-dependently reduced neutrophil accumulation in the gastric microcirculation and gastric damage. 52 These results have been con®rmed and extended by Appleyard et al using a number of structurally unrelated inhibitors of TNFa synthesis and an anti-TNFa antibody. 55 Another group of mediators that might contribute to the increase in neutrophil adherence following NSAID administration is the leukotrienes. Like prostaglandins, leukotrienes are derived from arachidonic acid. They have been shown to be capable of altering the susceptibility of the gastric mucosa to injury 44,56±58 , at least in part through stimulatory eects on neutrophil adherence to the vascular endothelium. 44 Inhibitors of leukotriene synthesis and leukotriene receptor antagonists have been shown to exert some protective eects in experimental models of NSAID-induced gastric damage.
56±58 There is also evidence of an elevated leukotriene B 4 production following NSAID administration to laboratory animals 44 and man 59 , and inhibitors of leukotriene synthesis and a leukotriene B 4 receptor antagonist have been shown to prevent NSAID-induced neutrophil adherence to the vascular endothelium both in vivo 44 and in vitro. 48 Evidence for a role for neutrophils in the pathogenesis of gastric ulceration in humans has recently been provided. 60 Patients taking NSAID therapy who had signi®-cant numbers of neutrophils within the gastric mucosa were approximately six times more likely to develop an ulcer over the course of 24 weeks than were patients who did not have signi®cant numbers of neutrophils in their gastric mucosa. It is also noteworthy that, in a clinical trial examining the potential bene®t of famotidine for the prevention of NSAID-related gastroduodenal ulcers, Taha et al observed that an increased peripheral white cell count was a signi®cant risk factor for ulcer development. 61 They suggested that this observation was consistent with the hypothesis that NSAID-induced gastropathy was mediated, at least partially, by neutrophils.
How would the adherence of neutrophils to the vascular endothelium contribute to the formation of gastroduodenal ulcers? First, the adherence of neutrophils to the vascular endothelium is accompanied by an activation of these cells, leading to the release of proteases (e.g. elastase and collagenase) and oxygen-derived free radicals (e.g. superoxide anions). These substances may mediate much of the endothelial and epithelial injury caused by NSAIDs. This is supported by observations that the severity of NSAID-induced mucosal injury can be markedly diminished by compounds that scavenge oxygen-derived free radicals 62, 63 and by inhibitors of neutrophil-derived proteases. 64, 65 Second, neutrophil adherence to the endothelium, and the subsequent recruitment of other elements of blood (e.g. platelets), could produce an obstruction of the capillaries, thereby reducing gastric mucosal blood¯ow. In this respect, it should be noted that the well-characterized ability of NSAIDs to reduce gastric blood ow 37±39 has been shown to occur subsequent to the appearance of`white thrombi' in the gastric microcirculation. 38 
INHIBITION OF RESTITUTION
Damage to the gastric epithelium probably occurs on a daily basis but does not usually lead to deeper mucosal injury because of the ability of rapid (i.e. within minutes) repair to occur via the process of restitution. This process involves the rapid migration of healthy cells from the gastric pits to re-establish an intact epithelial barrier. 66 The cells move along the denuded basement membrane, which acts as a template and has been shown to be crucial to the restitution process. 66±69 The basement membrane can be damaged by acid, leading to an inhibition of restitution and the progression of necrosis to deeper layers of the mucosa. 47, 70, 71 This does not, however, occur in normal circumstances because of the formation over sites of injury (i.e. exposed basement membrane) of a microenvironment in which the pH is maintained at near neutral, even in the presence of a signi®cant acid load in the lumen. 47, 70 A`mucoid cap' consisting of mucus, cellular debris and plasma proteins (particularly ®brin) forms within seconds of gastric epithelial injury, trapping the plasma that leaks from the underlying microcirculation. 70 It is this plasma which accounts for the near-neutral pH within the protective mucoid cap, since even a very brief cessation of mucosal blood¯ow results in a rapid decrease in the pH within the mucoid cap, which in turn results in the formation of haemorrhagic erosions.
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As discussed above, NSAIDs can decrease mucosal blood¯ow. Thus, NSAIDs can cause gastric injury by interfering with the appropriate function of the mucoid cap and therefore the process of restitution. Indeed, we observed that, following the systemic administration of an NSAID to an animal in which super®cial epithelial injury had been induced, the pH within the mucoid cap that had formed over the sites of epithelial damage began to decline in parallel with the inhibition of prostaglandin synthesis. 41 Within minutes thereafter, the formation of haemorrhagic erosions was clearly evident. This eect could be prevented through the luminal delivery of exogenous prostaglandins, as could the formation of haemorrhagic erosions.
REPAIR OF ULCERS
In addition to causing ulcer formation, NSAIDs can delay the healing of pre-existing ulcers and promote their bleeding. 72, 73 The eects on ulcer healing are probably related, once again, to the ability of NSAIDs to suppress prostaglandin synthesis. In normal gastric mucosa, prostaglandin synthesis occurs mainly via the cyclo-oxygenase-1 isoform. However, at a site of ulceration, and particularly around the ulcer margin, cyclo-oxygenase-2 appears to be the primary contributor to prostaglandin synthesis. Studies in mice and rats initially demonstrated the marked upregulation of cyclooxygenase-2 in ulcerated gastric tissue 74, 75 , and this has recently been con®rmed in humans. 76 Moreover, the treatment of rats or mice with selective inhibitors of cyclooxygenase-2 results in a signi®cant delay of ulcer healing.
74, 75 These observations, and reports of selective cyclo-oxygenase-2 inhibitors exacerbating intestinal in¯ammation and ulceration 77 , suggest that caution should be exercised in regarding the new cyclooxygenase-2 inhibitors as gastrointestinally safe. 78, 79 The ability of NSAIDs to promote the bleeding of pre-existing ulcers is most probably related to their inhibitory eects on platelet aggregation. 80, 81 The inhibition of platelet aggregation by NSAIDs occurs as a consequence of the inhibition of thromboxane synthesis. It should be noted that, unlike other NSAIDs, aspirin produces an irreversible inhibition of thromboxane synthesis in the platelet. Thus, even the low doses of aspirin used for the prophylaxis of myocardial infarction and stroke can signi®cantly increase the risk of gastrointestinal bleeding.
82±84

ROLE OF ACID
The observation that NSAID-induced ulcers can develop in achlorhydric individuals 29, 30 has contributed to a widely held belief that acid is not involved in the pathogenesis of these lesions. Further reinforcing this hypothesis are several studies demonstrating that treatment with histamine H 2 -receptor antagonists did not reduce the incidence of NSAID-induced ulceration. 85±87 However, many of these types of studies have demonstrated that H 2 -antagonists and proton pump inhibitors can prevent NSAID-induced gastric lesions, but not the formation of the clinically more signi®cant ulcers, as well as ulcer complications. Recently, however, Taha et al reported that a high dose of famotidine (40 mg twice daily) was eective in preventing NSAID-induced ulcers 61 , and Hawkey et al 88 demonstrated that omeprazole could signi®cantly reduce the incidence of NSAID-induced ulceration. These studies suggested that a profound suppression of acid secretion, as is produced by omeprazole or by a high dose of famotidine, was necessary in order to have a signi®cant impact on the incidence of NSAID-induced ulcers.
Acid may contribute to NSAID-induced ulcer formation in several ways. First, acid can exacerbate damage to the gastric mucosa induced by other agents. For example, acid can convert regions of ethanol-induced vascular congestion in the mucosa to actively bleeding erosions. 66 Second, acid will contribute to ulcer formation by interfering with haemostasis. Platelet aggregation, for example, is inhibited at a pH of less than 4. 89 Third, as outlined above, acid can convert super®cial injury to deeper mucosal necrosis by interfering with the process of restitution. Fourth, acid can inactivate several growth factors (e.g. ®broblast growth factor) that are important for the maintenance of mucosal integrity and for the repair of super®cial injury, since these growth factors are acid-labile. 90 It is important to note that NSAIDs can increase gastric acid secretion, although it is not clear whether such eects have any impact on ulcer formation or healing. Prostaglandins exert inhibitory eects on parietal cells 91 , so the inhibition of their synthesis by NSAIDs can result in an increase in gastric acid secretion. 92 
SUMMARY
A great deal has been learned about the pathogenesis of NSAID-induced gastric injury over the past two decades. As a result, several new NSAIDs, which will have greatly reduced gastrointestinal toxicity relative to current drugs, are in the process of being introduced to the marketplace. For example, selective inhibitors of cyclo-oxygenase-2, which will spare the major form of cyclo-oxygenase in the gastrointestinal tract, produce substantially less injury to the stomach than do the current NSAIDs that inhibit both cyclo-oxygenase-1 and -2.
93 Whether or not these agents prove to be as eective for the treatment of the full range of in¯ammatory conditions currently treated with NSAIDs remains to be seen, and some experimental studies suggest that this may not be the case.
94,95 Nitric oxide-releasing NSAIDs represent another approach to reducing the adverse eects of this class of drug. 96 The design of these new NSAIDs would not have been possible had it not been for an increased understanding of the pathogenesis of NSAID-induced ulceration.
